Enterprise Value
30.33M
Cash
492M
Avg Qtr Burn
-59.56M
Short % of Float
27.26%
Insider Ownership
29.44%
Institutional Own.
98.59%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ALLO-501A (CD19) Details Non-Hodgkin lymphoma, Cancer, Diffuse large B cell lymphoma | Phase 2 Data readout | |
ALLO-647 (Anti-CD52 mAb) Details Cancer, Diffuse large B cell lymphoma | Phase 2 Update | |
ALLO-316 (CD70) Details Solid tumor/s, Renal cell carcinoma, Cancer | Phase 1 Data readout | |
ALLO-715 (BCMA) Details Cancer, Multiple myeloma | Phase 1 Update | |
ALLO-605 (BCMA) Details Cancer, Multiple myeloma | Phase 1 Update |